TDP-43, a DNA- and RNA-binding protein, plays a pivotal role in RNA metabolism and neuronal health. Mislocalization and aggregation of TDP-43 are hallmark features in the vast majority of ALS cases and in a significant subset of FTD patients, making it a focal point of neurodegenerative research. However, treatments directly modulating TDP-43 have been hampered by its essential cellular functions and the complex downstream effects of its pathology. The study conducted by Amado, Robbins, Whiteman, and colleagues pioneers an indirect yet potent way to mitigate TDP-43 toxicity by silencing ataxin-2 expression through an RNAi mechanism conveyed by an AAV vector.

Ataxin-2, though traditionally associated with spinocerebellar ataxia type 2 (SCA2), has recently emerged as a genetic modifier influencing TDP-43-mediated neurodegeneration. Previous genetic and biochemical studies have implicated ataxin-2 as a crucial interactor of TDP-43, modulating its aggregation propensity and cytotoxicity. The authors hypothesized that partial reduction of ataxin-2 levels could alleviate TDP-43’s deleterious effects without invoking the severe side effects linked to complete knockdown.

To examine this hypothesis, the research team employed an innovative AAV vector system designed for efficient delivery and sustained expression of RNAi molecules targeting ataxin-2 mRNA. This vector exploits the benign nature of AAVs, their neurotropism, and long-term gene silencing capacity. They administered the AAV-RNAi construct intracerebroventricularly into TDP-43 transgenic mice, a widely accepted preclinical model that recapitulates key aspects of TDP-43 proteinopathy, including motor neuron degeneration and shortened lifespan.

The results were nothing short of remarkable. Mice treated with the AAV-RNAi construct exhibited a significant extension in survival compared to controls. Behavioral assessments revealed marked improvements in motor coordination and grip strength, underscoring the functional preservation achieved by ataxin-2 knockdown. Histopathological analyses corroborated these findings, demonstrating reduced TDP-43 aggregation, diminished neuroinflammation, and preservation of motor neuron populations in the spinal cord and motor cortex.

The mechanism underlying this therapeutic effect appears to revolve around a delicate rebalancing of RNA metabolism and protein homeostasis. Ataxin-2 reduction attenuates pathological stress granule dynamics and mitigates aberrant phase transitions implicated in TDP-43 aggregation. By modulating these molecular pathways, the intervention restores neuronal resilience and slows the cascade of neurodegenerative events.

Importantly, the study provides extensive safety data affirming that the partial suppression of ataxin-2 via RNAi does not induce overt toxicity or adversely affect normal neuronal function. This addresses a critical concern given that ataxin-2 also engages in physiological roles within RNA processing networks. The targeted and tunable nature of RNAi delivered by AAV vectors offers an optimal therapeutic window, maximizing efficacy while minimizing risks.

The translational implications of these findings are profound. Gene therapy platforms leveraging AAV vectors are already established as feasible for human use, with several approved therapeutics for monogenic diseases. This study’s demonstration that such a platform can be repurposed to deliver RNAi against a modifier gene in complex neurodegeneration charts a new frontier in precision medicine. It opens up opportunities for bespoke gene silencing treatments tailored to genetic profiles and disease mechanisms.

Moreover, this strategy could synergize with emerging TDP-43-targeted therapies, combining upstream modulation of toxic aggregations with downstream correction of pathological cascades. Such combinatorial approaches may ultimately yield durable clinical benefits for patients afflicted with ALS, FTD, and related disorders, diseases for which effective treatments remain limited.

Beyond the immediate clinical potential, the work by Amado and colleagues deepens our understanding of the pathological interplay between TDP-43 and ataxin-2. It highlights the utility of modulating protein interactors as a therapeutic avenue, shifting the paradigm from directly targeting the aggregation-prone proteins themselves toward their regulatory networks. This may inform intervention strategies across a spectrum of protein misfolding diseases.

The utilization of RNAi technology also underscores the escalating precision of genetic medicine. By enabling selective gene silencing with spatial and temporal control, RNAi therapies offer a powerful tool to manipulate disease modifiers without permanent genomic alterations. AAV vectors’ capacity for targeted neuronal delivery and sustained expression further enhances the therapeutic profile.

Technically, the study exemplifies cutting-edge vector design and validation. The team engineered an AAV serotype optimized for central nervous system transduction, incorporating a robust promoter to drive RNAi expression within affected neuronal populations. Rigorous in vivo dosing studies established an effective concentration that balances potent knockdown with tolerability. The longitudinal experimental framework, incorporating molecular, behavioral, and histological endpoints, paints a comprehensive picture of therapeutic impact.

This breakthrough also prompts consideration of the challenges ahead. Scaling this therapy for human application will demand meticulous optimization of vector production, delivery routes, dosing parameters, and long-term safety monitoring. Potential immunogenicity of viral vectors and off-target RNAi effects remain important areas for further investigation. Nevertheless, the preclinical success lays a strong foundation.

The broader neuroscientific community is likely to find this approach inspiring. It exemplifies the synergy achievable when gene therapy intersects with detailed mechanistic insights into disease biology. Such convergence propels us toward the long-sought goal of modifying neurodegeneration’s relentless course.

In summary, this landmark work delineates a transformative gene therapy strategy leveraging AAV-mediated RNAi targeting ataxin-2 to rescue survival and neuropathology in a TDP-43 mouse model. The therapeutic promise, mechanistic sophistication, and translational readiness combine to illuminate a hopeful path forward for devastating neurodegenerative diseases marked by TDP-43 dysfunction. As the scientific and clinical fields advance, such innovations will be vital in shaping the future landscape of neurotherapeutics.

Subject of Research: Neurodegeneration, TDP-43 proteinopathy, RNA interference, gene therapy

Article Title: AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice

Article References:
Amado, D.A., Robbins, A.B., Whiteman, K.R. et al. AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice. Nat Commun 16, 5334 (2025). https://doi.org/10.1038/s41467-025-60497-8

Image Credits: AI Generated

The 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in New Orleans has become a significant platform for ground-breaking advances in gene and cell therapy presented by leading researchers from Mass General Brigham and its dedicated Gene and Cell Therapy Institute. This emergence of innovative research is rapidly transforming the landscape of treatment for some of the most complex and devastating diseases, particularly those with unmet medical needs such as neurodegenerative disorders, rare genetic syndromes, and aggressive brain cancers.

Mass General Brigham’s Gene and Cell Therapy Institute, established in 2022, is a beacon of translational research that amalgamates the expertise of over 500 scientists and clinicians focused on charting new territories in genetic medicine. Their commitment to pioneering therapeutic modalities that transition from bench to bedside has been highlighted through a series of compelling presentations that showcase novel delivery systems, engineered vectors, and sophisticated cellular platforms capable of targeting diseases at the molecular and cellular levels.

Among the standout presentations is the study on optimizing focused ultrasound (FUS) parameters to enhance adeno-associated virus (AAV) vector delivery across the notoriously impermeable blood-brain barrier (BBB). The impermeability of the BBB has long posed a formidable challenge in delivering gene therapies to the central nervous system, restricting therapeutic efficacy. Researchers led by Bernie Owusu-Yaw, PhD, demonstrated that transient BBB opening with focused ultrasound coupled with microbubbles dramatically increased neuronal transduction without causing tissue damage. Intriguingly, their results suggest the complexity of BBB dynamics as the volume of barrier opening did not directly correlate with gene delivery efficiency, pointing to nuanced biological mechanisms that govern viral vector penetration.

In a complementary domain, Elie Roumieh, MD, presented a sophisticated human cell-based platform developed to test olfactory ensheathing cells (OECs) as vectors for cancer gene therapy targeting gliomas. OECs’ unique migratory capacity and natural affinity for CNS tumor sites position them as promising candidates for delivering therapeutic transgenes directly to malignancies. Using hiPSC-derived brain-glioma assembloids—a co-culture system combining human cerebral organoids with glioma cells—the research team successfully depicted extensive tumor invasion and validated OEC identity via markers like p75NGFR and MPZ. These culture systems offer unprecedented human-relevant models for dissecting OEC-tumor interactions and potentiating cell-based targeted therapies.

Aarushi Gandhi, PhD, shed light on the pathophysiology and treatment potential for Multisystemic Smooth Muscle Dysfunction Syndrome (MSMDS), a crippling monogenic disorder caused by mutations in the ACTA2 gene. Their innovative murine model harbored a conditional R179H knock-in mutation replicating the human disease phenotype, including vascular shear stress and neurological deterioration due to BBB disruption. Strikingly, by leveraging CRISPR-Cas9 adenine base editing delivered via AAV vectors, the group reversed the ACTA2 mutation in vivo. Restoration of smooth muscle functionality correlated with reduced BBB permeability and attenuation of neurodegenerative processes, demonstrating a promising gene-editing therapeutic avenue to tackle ultrarare genetic vascular disorders.

Mass General Brigham researchers also introduced the RISE framework—proposed by Nandhitha Uma Naresh, PhD—to overcome translational bottlenecks that academic medical centers (AMCs) frequently encounter in advancing cell and gene therapies (CGTs). RISE advocates for four critical pillars: Resource sharing, Interdisciplinary collaboration, Sustainable funding, and Educational outreach. This strategic model underscores the necessity for comprehensive institutional support beyond mere funding, aiming to bridge the translational valley of death that hinders many innovative academic therapies from reaching clinical application.

Nick Todd, PhD, expanded upon the FUS paradigm with compelling preclinical evidence demonstrating the clinical translatability of combining focused ultrasound with a novel engineered AAV capsid, AAV.CPP16. This engineered capsid incorporates cell-penetrating peptides to enhance BBB penetration and neuronal tropism. Using a state-of-the-art human clinical FUS system, they successfully delivered the vector systemically in both rat and non-human primate (NHP) models. MRI-guided sonication with real-time feedback allowed precise opening of deep brain regions without hemorrhagic complications. The observed robust neuronal transduction at remarkably low viral doses bolsters the promise of this minimally invasive platform for treating neurological diseases with high spatial precision and safety.

On the pulmonary front, Yan Tang, PhD, unveiled pioneering gene replacement strategies for pulmonary lymphangioleiomyomatosis (LAM), a rare disease driven by mutations in tumor suppressors TSC1 or TSC2 leading to mTORC1 hyperactivation. Current FDA-approved treatments like sirolimus attenuate progression but fail to halt disease entirely, with many patients ultimately requiring lung transplantation. Utilizing lipid nanoparticle (LNP) technology to deliver functional mouse Tsc2 mRNA in a preclinical model, researchers accomplished significant tumor burden reduction. This LNP-based mRNA therapy restores tumor suppressor activity at the cellular level, highlighting a scalable therapeutic platform that could potentially revolutionize treatment for LAM and similar monogenic pulmonary conditions.

The collective advances presented at ASGCT 2025 epitomize a paradigm shift in gene and cell therapy, where multipronged approaches—including mechanical techniques like FUS, genetic correction via CRISPR base editing, and innovative cellular vector platforms—coalesce to overcome biological barriers long deemed insurmountable. Mass General Brigham’s concerted focus on rare and ultrarare diseases further underscores the commitment to addressing neglected patient populations with high unmet need, forging pathways toward durable, curative solutions.

Beyond the scientific breakthroughs, the institute’s strategic vision and collaborative ecosystem are pivotal in catalyzing these innovations. By integrating clinical research, preclinical modeling, and advanced biotechnology, Mass General Brigham leverages the confluence of cutting-edge science and translational medicine. Their presentations at the ASGCT meeting not only showcase the feasibility and safety of sophisticated gene therapy delivery systems but also lay the groundwork for future clinical trials that will bring these promising therapies closer to real-world implementation.

In sum, the ASGCT 2025 presentations from Mass General Brigham reveal how advanced gene editing, novel vector engineering, non-invasive targeting strategies, and robust cellular platforms are transforming the therapeutic landscape. These innovations carry the potential to significantly improve patient outcomes across a spectrum of debilitating genetic and degenerative diseases, signaling a new era where the integration of gene and cell therapies will become a mainstay of personalized medicine.

Subject of Research: Gene and cell therapy advancements targeting neurodegenerative diseases, brain cancer, rare genetic syndromes, and pulmonary lymphangioleiomyomatosis (LAM).

Article Title: Pushing the Frontiers of Gene and Cell Therapy: Mass General Brigham’s Breakthrough Research Unveiled at ASGCT 2025

News Publication Date: 2025 (May 13-17)

Web References:

• Mass General Brigham — https://www.massgeneralbrigham.org/en
• ASGCT Annual Meeting Abstracts — https://annualmeeting.asgct.org/abstracts
• Dropbox link to abstracts (provided in source content)

Keywords: Gene editing, Gene delivery, Medical treatments, Gene therapy, Focused ultrasound, Blood-brain barrier, CRISPR base editing, AAV vectors, Olfactory ensheathing cells, Pulmonary lymphangioleiomyomatosis, Lipid nanoparticle mRNA therapy, Cell and gene therapy innovation